Healthy Lactating Women
5
1
1
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
7 treatments under study, led by Tafenoquine
Research Leaders
6 sponsors active, led by Supernus Pharmaceuticals Inc
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 5 trials
100.0%
+13.4% vs benchmark
100%
5 trials in Phase 3/4
100%
3 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (5)
Evaluation of the Excretion of Fosfomycin Into Breast Milk Following a Single Intravenous Dose of ZTI-01 (6 g) in Healthy Lactating Women
Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women
Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women
Tafenoquine and Primaquine in Colostrum and Breast Milk
A Study Of Pregabalin (Lyrica) Drug Levels In Urine, Plasma And Breast Milk Of Healthy Lactating Women
Research Network
Common Treatments
- Tafenoquine1
- Bempedoic Acid 180 Mg Oral Tablet1
- Primaquine1
- Bempedoic Acidezetimibe 180 Mg10 Mg Oral Tablet1
- Spn812 600mg Qd1
Active Sponsors
- Supernus Pharmaceuticals Inc1
- Meitheal Pharmaceuticals Inc1
- Pfizers Upjohn Has Merged With Mylan To Form Viatris Inc1
- University Of Oxford1
- Mahidol Oxford Tropical Medicine Research Unit1